Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Senate GOP Could Use Procedural Tactics To Delay Sotomayor Hearings
Senate Minority Whip Jon Kyl (R-Ariz.), a member of the Senate Judiciary Committee, on Thursday said that the GOP has not ruled out the use of procedural tactics, such as a Republican boycott, to attempt to delay Supreme Court nominee Sonia Sotomayor"s confirmation hearing, Roll Call reports. Republicans have complained that the scheduled July 13 start date for the hearing does not give them enough time to review Sotomayor"s record. Kyl said that Republicans will try to negotiate with Senate Judiciary Committee Chair Patrick Leahy (D-Vt.) for more time if they feel they cannot meet the July 13 deadline (Stanton, Roll Call, 6/11). Leahy said that Sotomayor is entitled to be confirmed on the same timetable as Chief Justice John Roberts, who appeared before the Judiciary Committee less than two months after his nomination (Kivlan, CongressDaily, 6/11).Republican Senate aides say Judiciary Committee ranking member Jeff Sessions (R-Ala.) is not likely to make a final decision for several weeks on whether the GOP will try to delay the nomination. According to Roll Call, Sessions has sought to approach the issue "in a careful, measured way," though he has been critical of some of Sotomayor"s public statements. Roll Call reports that Republicans are apt to display an impartial stance on Sotomayor until the hearing starts, meaning that they likely will delay a decision on whether to stall the nomination until the last minute (Roll Call, 6/11).Sen. Dianne Feinstein (D-Calif.) said that Republican senators are stalling to give conservative groups more time to organize a campaign against Sotomayor that they hope will taint her nomination. Feinstein said that there are "groups out there who need more time for attacks and sound bites." She added, "This is a woman who is qualified, who is brilliant, and who worked her way up" (CongressDaily, 6/11).
generic viagra online
IPS Examines Legislative Measures To Fight HIV/AIDS
Inter Press Service examines several civil society organizations" argument that legislative measures aimed at fighting HIV/AIDS, "hurt more" than they "help." There are 58 countries with laws in place to "prosecute HIV transmission" and 33 others where such legislation is being considered, according to the International Planned Parenthood Federation.
News of the day
Infant Inhalation Of Ultrafine Air Pollution Linked To Adult Lung Disease: Shown For The First Time By LSUHSC
Stephania Cormier, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, has shown for the first time that early exposure to environmentally persistent free radicals (present in airborne ultrafine particulate matter) affects long-term lung function. She recently presented her latest research data at the 11th International Congress on Combustion By-Products and Their Health Effects at the Environmental Protection Agency Conference Center in Research Triangle Park, N.C.
Sexual Health

Invatec Officially Launches Coronary Drug-Eluting Balloon Platform IN.PACT™ Falcon At EuroPCR

Invatec, a comprehensive innovator of interventional products, today announced the availability of its newly CE marked coronary balloon, the IN.PACT™ Falcon paclitaxel-eluting PTCA balloon catheter at the EuroPCR Congress 2009 in Barcelona, Spain. This is one of the first drug-eluting balloons designed specifically to treat atherosclerosis in the coronary arteries and underscores Invatec"s commitment to robust scientific research into the reduction of re-intervention rates in the treatment of Coronary Artery Disease (CAD). Prof. Eberhard Grube, Chief, Department of Cardiology/Angiology at the Heart Center, Siegburg, Germany, commented, "Combining world-class PTCA balloon catheter technology with local drug administration is a fascinating new concept for the treatment of certain coronary lesions such as In-Stent Restenosis (ISR), Small Vessel Disease (SVD), Bifurcations and potentially other lesions where conventional balloons, stents and even drug eluting stents may not be ideal. A drug eluting balloon such as the IN.PACT Falcon that elutes a known and effective drug such as Paclitaxel holds much promise as an effective treatment option for patients." IN.PACT Falcon combines the currently marketed, performance leading Falcon line of PTCA balloon catheters with Invatec"s proprietary IN.PACT technology platform and FreePac™ coating. FreePac is a proprietary, natural coating that frees and separates paclitaxel molecules and facilitates their absorption into the wall of the artery. The FreePac coating was developed in close collaboration with the researchers who pioneered drug-eluting balloon therapy, Ulrich Speck, Ph.D., Department of Radiology at Charite Mitte, Berlin and Bruno Scheller, M.D., University Hospital, Department of Internal Medicine, Homburg/Saar. "We are extremely excited to commercialize a much-needed product that combines our FreePac coating technology with the performance-leading characteristics of our Falcon PTCA balloon platform, thereby creating a world class drug eluting balloon," commented Andrea Venturelli and Stefan Widensohler, co-founders of Invatec. "The European availability of IN.PACT Falcon underscores our mission to provide physicians with the option of using drug eluting balloons for specific clinical indications throughout the coronary and peripheral anatomy. The launch of IN.PACT Falcon also aligns with our strategy to leverage FreePac on all of our major balloon platforms. We see an immediate opportunity for the IN.PACT Falcon to treat patients with In Stent Restenosis (ISR) and plan to proceed with an ambitious clinical research program to further study the use of IN.PACT Falcon to treat Small Vessel Disease and de novo lesions. " Invatec


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009